HC Wainwright Issues Pessimistic Outlook for HRTX Earnings

Heron Therapeutics, Inc. (NASDAQ:HRTX) – HC Wainwright lowered their FY2026 earnings per share estimates for Heron Therapeutics in a research note issued on Wednesday, November 11th. HC Wainwright analyst B. Folkes now expects that the biotechnology company will post earnings per share of ($0.15) for the year, down from their prior estimate of ($0.14). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Heron Therapeutics’ current full-year earnings is ($0.14) per share. HC Wainwright also issued estimates for Heron Therapeutics’ Q4 2026 earnings at ($0.04) EPS, FY2027 earnings at ($0.14) EPS, FY2028 earnings at ($0.09) EPS and FY2029 earnings at ($0.03) EPS.

A number of other equities analysts have also recently issued reports on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Heron Therapeutics in a report on Thursday, October 15th. Zacks Research raised Heron Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, August 3rd. Finally, Wall Street Zen raised Heron Therapeutics to a “sell” rating in a report on Saturday, August 8th. Three investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Heron Therapeutics currently has a consensus rating of “Reduce” and a consensus price target of $2.00.

Heron Therapeutics Price Performance

Shares of NASDAQ:HRTX opened at $0.33 on Friday. The company has a market cap of $62.01 million, a PE ratio of -2.72 and a beta of 1.65. Heron Therapeutics has a fifty-two week low of $0.26 and a fifty-two week high of $1.57. The firm has a 50-day simple moving average of $0.33 and a 200 day simple moving average of $0.65. The company has a quick ratio of 1.51, a current ratio of 2.33 and a debt-to-equity ratio of 32.59.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Monday, November 9th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.03). Heron Therapeutics had a negative net margin of 14.55% and a negative return on equity of 277.36%. The company had revenue of $35.25 million for the quarter, compared to the consensus estimate of $37.50 million.

Hedge Funds Weigh In On Heron Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. HORAN Wealth LLC bought a new position in shares of Heron Therapeutics during the first quarter worth about $33,000. Deutsche Bank AG bought a new stake in Heron Therapeutics in the 2nd quarter valued at about $41,000. Ieq Capital LLC bought a new stake in Heron Therapeutics in the 2nd quarter valued at about $41,000. Bank of America Corp DE bought a new stake in Heron Therapeutics in the 2nd quarter valued at about $46,000. Finally, Persistent Asset Partners Ltd acquired a new position in Heron Therapeutics during the 2nd quarter valued at about $50,000. Institutional investors and hedge funds own 80.01% of the company’s stock.

About Heron Therapeutics

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on developing and marketing medicines for acute care and oncology supportive care. Its products are designed to address unmet needs such as postoperative pain and chemotherapy-induced nausea and vomiting. The company’s portfolio includes ZYNRELEF, an extended-release solution combining bupivacaine and meloxicam for the management of postoperative pain in adults. Heron also markets CINVANTI, an injectable formulation of aprepitant used as part of a combination regimen to help prevent acute and delayed nausea and vomiting associated with highly or moderately emetogenic cancer chemotherapy.